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Abstract
Brain tumor initiating cells (BTICs), also known as cancer stem cells, hijack high-affinity glucose 
uptake active normally in neurons to maintain energy demands. Here we link metabolic 
dysregulation in human BTICs to a nexus between MYC and de novo purine synthesis, mediating 
glucose-sustained anabolic metabolism. Inhibiting purine synthesis abrogated BTIC growth, self-
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renewal and in vivo tumor formation by depleting intracellular pools of purine nucleotides, 
supporting purine synthesis as a potential therapeutic point of fragility. In contrast, differentiated 
glioma cells were unaffected by the targeting of purine biosynthetic enzymes, suggesting selective 
dependence of BTICs. MYC coordinated the control of purine synthetic enzymes, supporting its 
role in metabolic reprogramming. Elevated expression of purine synthetic enzymes correlated with 
poor prognosis in glioblastoma patients. Collectively, our results suggest that stem-like glioma 
cells reprogram their metabolism to self-renew and fuel the tumor hierarchy, revealing potential 
BTIC cancer dependencies amenable to targeted therapy.
Glioblastoma (World Health Organization grade IV glioma) is the most prevalent and 
malignant primary intrinsic brain tumor, with current therapies offering only palliation for 
patients1. Glioblastomas display intratumoral heterogeneity stemming from genetic and 
epigenetic aberrations. Functional diversity exists within this heterogeneity in the form of a 
cellular hierarchy maintained by self-renewing brain tumor initiating cells (BTICs)2. While 
BTICs recapitulate self-renewal and differentiation, partially mimicking neural precursor 
cells (NPCs)3, BTICs demonstrate distinguishing features, including increased frequency, 
proliferation, aberrant expression of stem and progenitor cell markers, and tumor formation. 
The importance of BTICs is underscored by their relative resistance to radiation and 
chemotherapy as compared to non-stem or differentiated glioma cells (DGCs)4,5. This 
resistance may contribute to tumor recurrence and relapse. BTICs also promote angiogenesis 
and tumor invasion, potentially limiting the efficacy of antiangiogenic agents6,7. Therefore, 
targeting BTICs may be important for improved outcomes for glioblastoma patients.
The normal brain potently extracts circulating glucose to provide energy required for organ 
function. Metabolic reprogramming, namely the Warburg effect, is recognized as a key 
hallmark of cancer, including brain tumors8. Tumor cells preferentially rely on glycolysis, 
rather than the mitochondrial oxidative phosphorylation used in nonmalignant cells, to 
generate ATP9,10. Although energetically inefficient, this phenomenon may provide cancer 
cells with the key ability to channel glycolytic intermediates into anabolic biosynthesis, 
enabling rapid tumor growth even under hypoxia. Metabolic reprograming in cancer is not 
simply a passenger in tumorigenesis, but may be an initiating event, as recurrent somatic 
mutations of metabolic enzymes have been reported10. Neomorphic mutations in isocitrate 
dehydrogenase 1 or 2 (IDH1 and IDH2, respectively) occur in most low-grade gliomas and 
recurrent glioblastomas11. The mutant IDH1 or IDH2 produces 2-hydroxyglutarate, an 
oncometabolite, generating global epigenetic alterations associated with tumor initiation and 
progression12.
Adaptation to the varied microenvironments in the brain ecosystem is essential to tumor 
maintenance and progression. Stressful conditions, such as hypoxia, low glucose or low pH, 
maintain BTICs13-15. We previously showed that BTICs upregulate GLUT3 (solute carrier 
family 2 (facilitated glucose transporter), member 3; SLC2A3), a neuronal survival 
mechanism, to compete for glucose in response to nutrient supply fluctuations13. The 
GLUT3 transporter has fivefold greater affinity for glucose than the ubiquitously expressed 
GLUT1 protein, creating an increased glucose influx and secured carbon flow in normal 
neurons and BTICs. Similar phenomena also exist in embryonic stem cells and induced 
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pluripotent stem cells, suggesting similarity in signaling pathways between pluripotent stem 
cells and BTICs10,16. Glucose also induces resistance to targeted therapy through the 
promotion of protein acetylation17. Clinically, hyperglycemia and overexpression of GLUT3 
predict shorter survival in glioblastoma patients13,18. The precise mechanism of how BTICs 
reprogram the metabolic machinery to sustain glucose influx, promote self-renewal and 
maintain tumorigenic capacity is unknown.
We traced the downstream carbon flow following glucose influx, using unbiased 
metabolomic profiling and in silico genomic discovery. Carbon influx in BTICs was used to 
sustain de novo purine synthesis, maintained by the core transcription factor MYC. As 
metabolic reprogramming represents a unique BTIC signature stemming from both intrinsic 
and extrinsic influences, this study reveals new metabolic nodes for improved glioblastoma 
therapeutics.
RESULTS
Combined metabolomic and genomic analyses reveal specific upregulation of de novo 
purine synthesis in BTICs
To determine the downstream metabolic reprogramming events associated with elevated 
glucose uptake in BTICs, we performed extensive molecular characterization of patient-
derived BTIC xenograft models that we previously showed to contain functional cellular 
hierarchies13-15. Whole-exome sequencing, RNA sequencing (RNA-seq) and whole-genome 
DNA methylation analysis revealed that these models replicate key features of the genetics 
and transcriptional signatures of glioblastoma, when compared to data extracted from The 
Cancer Genome Atlas (TCGA) (Supplementary Fig. 1a–d). Using these models, we 
performed unbiased carbon tracing of two glioblastoma patient-derived BTICs and matched 
DGCs with [13C6]glucose, followed by nontargeted small molecule mass spectrometry. We 
scored each metabolite by calculating the relative 13C incorporation in BTICs over patient-
matched DGCs. Among the top hits were metabolites in the de novo purine synthesis 
pathway, such as inosine 5′-monophosphate (IMP), adenosine 5′-monophosphate (AMP), 
adenine and guanine (Fig. 1a,b). However, the level of ribose 5-phosphate (R5P), the starting 
substrate of de novo purine synthesis, was not significantly different between BTICs and 
DGCs (data not shown). We thus hypothesized that the de novo purine pathway is 
preferentially used in BTICs. Using targeted small molecule mass spectrometry, we 
confirmed elevated levels of IMP, AMP and guanosine monophosphate (GMP) in BTICs in 
five patient-derived glioblastoma models (Fig. 1c–e). The level of hypoxanthine, a purine 
degradation product, was also elevated in BTICs (Supplementary Fig. 2a), diminishing the 
possibility that blockage in the purine degradation pathway causes the observed higher levels 
of IMP, AMP and GMP. Collectively, these results support the idea that one outcome of 
increased glucose intake of BTICs is shuttling of carbon atoms preferentially into de novo 
purine synthesis.
To determine the molecular pathways involved in the increased BTIC purine synthesis, we 
assessed the gene expression pattern of core enzymes involved in purine synthesis in patient-
derived samples from the TCGA glioblastoma data set19,20. PRPS1 (phosphoribosyl 
pyrophosphate synthetase 1) and PPAT (phosphoribosyl pyrophosphate amidotransferase) 
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function in the main branch synthesizing IMP from R5P. Downstream of IMP, the pathway 
branches in two to synthesize AMP and GMP. Their syntheses are catalyzed, respectively, by 
ADSS (adenylosuccinate synthase) plus ADSL (adenylosuccinate lyase) and by IMPDH1 
(IMP dehydrogenase 1) plus GMPS (guanine monophosphate synthase). The expression of 
genes encoding these six enzymes significantly and positively correlated with one another 
across 530 glioblastoma tumor samples analyzed (Fig. 1f). The correlation coefficient 
between ADSS and GMPS was as high as 0.481, supporting the coordinated regulation of 
genes involved in the purine synthesis pathway in glioblastoma specimens. Using 
immunoblot analysis, the expression levels of three purine synthesis enzymes, PRPS1, 
ADSL and GMPS—each representing an arm of the purine biosynthesis pathway—were 
significantly elevated in BTICs as compared to matched DGCs (Fig. 1g). As the most 
commonly used BTIC marker, CD133, is not universally informative for BTICs, we 
confirmed our findings using an independent surface marker for stemness in human 
glioblastoma, CD15 (SSEA-1)21. We derived matched populations of CD15+ and CD15− 
tumor cells from two fresh surgical glioblastoma specimens in the absence of any culture to 
avoid derivation bias. The expression levels of all six de novo purine biosynthetic pathway 
genes were upregulated in BTICs compared to those in DGCs (Supplementary Fig. 2b,c).
Elevated levels of purines and their biosynthetic enzymes in BTICs suggest that BTICs may 
be sensitive to inhibition of this pathway. Therefore, we treated a series of patient-derived 
BTIC models with three pharmacologic inhibitors of purine biosynthesis: mycophenolic 
acid, mycophenolate mofetil and ribavirin. BTIC proliferation was attenuated with 
mycophenolic acid and mycophenolate mofetil at submicromolar concentrations (Fig. 1h,i), 
whereas ribavirin inhibited BTIC proliferation at higher concentrations (Fig. 1j). Similar 
concentration ranges of these three inhibitors had no effect on DGC proliferation 
(Supplementary Fig. 3a–c), supporting a specific role of de novo purine synthesis in BTICs. 
Treatment of two BTIC models with 5 μM mycophenolic acid, 5 μM mycophenolate mofetil 
or 50 μM ribavirin all caused significant reduction in GMP, assessed with targeted mass 
spectrometry (Supplementary Fig. 3d–f). Further, treatment with an intermediate of inosine 
monophosphate production, AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), an 
AMP analog, suppressed BTIC proliferation (Supplementary Fig. 3g–j). While AICAR is 
considered an activator of AMP kinase, recent reports support an AMP kinase–independent 
mechanism in glioblastoma22,23.
To evaluate the genomic upregulation of de novo purine synthesis pathway in BTICs, we 
performed genome-wide histone H3 Lys27 acetylation chromatin immunoprecipitation 
followed by deep sequencing (H3K27ac ChIP-seq) on a matched pair of BTICs and DGCs 
to map active enhancers and promoters. The differential chromatin regulation of H3K27ac 
levels at specific enhancers was compared between BTICs and DGCs (Fig. 2a,b). Unbiased 
enrichment analysis of all metabolic pathways identified the upregulation of H3K27ac at 
nucleotide synthesis pathway and particularly purine synthesis pathway genes in BTICs 
(Fig. 2c, Supplementary Fig. 4a and Supplementary Table 1). Focused analysis was 
performed at the promoter regions for genes involved in four key metabolic pathways: 
glutathione, glycolysis, pentose phosphate and purine pathways. Active chromatin (as 
demonstrated by H3K27 acetylation) for all four metabolic pathways was increased in 
BTICs compared to DGCs, with the strongest differential regulation in purine synthesis 
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pathway genes (Fig. 2d–g). We then performed RNA-seq using the same matched pair of 
BTICs and DGCs to characterize the expression profiles. Analysis of the above four 
metabolic pathways revealed selective upregulation of purine synthesis pathway in BTICs 
(Supplementary Fig. 4b–e). In contrast, no consistent differential regulation was observed 
for the other three metabolic pathways. Our combined efforts of metabolomic profiling and 
genomic discovery demonstrate that BTICs specifically activate de novo purine synthesis, 
supporting purine biosynthesis as a potential point of sensitivity in resistant brain tumor 
populations.
Glycolytic activity modulates de novo purine synthesis in BTICs
Preferential activation of purine synthesis in BTICs prompted us to investigate its metabolic 
significance in processing increased carbon flow through glycolysis. Standard cell culture 
conditions provide glucose at supraphysiologic levels to facilitate unrestricted proliferation, 
but these artificial conditions fail to replicate nutrient availability in tumors. To mimic tumor 
conditions, we grew BTICs with 0.45 g/L glucose, which is one-tenth of that in standard cell 
culture conditions, for 2 d. Short-term (48 h) glucose restriction of BTICs decreased mRNA 
levels of several molecular precursor markers, including SOX2, NES and OLIG2, and 
increased mRNA levels of differentiation markers, including GFAP and MBP 
(Supplementary Fig. 5a–c). In contrast, long-term glucose restriction for 7 d in BTICs 
induced a twofold increase in precursor markers of SOX2, NES and OLIG2, and significant 
decrease in differentiation markers of GFAP and MBPF, indicating metabolic 
reprogramming in BTIC in response to metabolic stress (Supplementary Fig. 5d–f), as is 
consistent with our previous report13. To evaluate the role of purine synthesis in maintaining 
BTIC stemness, we examined the effect of short-term glucose restriction of 48 h on mRNA 
levels of genes encoding all six purine synthetic enzymes. All six were decreased (Fig. 3a–
c). This was also observed at the protein levels for PRPS1, ADSL and GMPS (Fig. 3d). 
Concordantly, levels of purine synthetic intermediates IMP, AMP and GMP were all 
decreased in BTICs under glucose-restricted conditions (Fig. 3e), establishing a tight 
connection between glucose uptake and downstream purine synthesis activity. We then used 
2-deoxyglucose (2-DG), an inhibitor of glycolysis, to mimic glucose depletion under 
standard glucose conditions. Upon treatment with 10 mM 2-DG for 2 d, BTICs 
downregulated the transcription of genes involved in purine synthesis by 50–80% (Fig. 3f–
h). Change of mRNA levels corresponded with decreased protein levels of PRPS1, ADSL 
and GMPS after 2-DG treatment (Fig. 3i) and the levels of purine intermediates, including 
IMP, AMP and GMP (Fig. 3j).
As the GLUT3 transporter mediates preferential glucose uptake in BTICs13, we examined 
the link between GLUT3 and purine synthesis activity. Using two independent short hairpin 
RNAs against the GLUT3 (SLC2A3) gene, we successfully knocked down GLUT3 
expression by over 80% compared to control nontargeting shRNA (shCont) (Supplementary 
Fig. 5g). Upon GLUT3 depletion in BTICs, mRNA levels of purine synthesis pathway genes 
decreased (Supplementary Fig. 5h–j). Concordantly, GLUT3 knockdown reduced the protein 
levels of PRPS1, ADSL and GMPS (Fig. 3k).
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As glucose is not the sole carbon source in brain and cancer metabolism, we further 
interrogated the role of additional metabolic sources such as glutamine and acetate in the 
context of glucose restriction. Induced glucose deprivation in two BTIC models caused loss 
of cell viability (Supplementary Fig. 5k,l). Glutamine partially rescued cell viability, while 
adding acetate showed no significant benefit (Supplementary Fig. 5k,l). Glutamine is a 
known nitrogen source for metabolic reprogramming in cancer cells24, so we analyzed the 
contribution of nitrogen from glutamine to synthesize purine in BTICs. Using a 
[15N2]glutamine tracer, we found that glutamine contributed nitrogen atoms to purine 
synthesis (Supplementary Fig. 6). These data confirm a link between GLUT3-mediated 
glucose influx and the functional activation of de novo purine synthesis in BTICs, creating 
critical metabolic support for BTIC maintenance.
The transcription factor MYC regulates purine synthesis pathway in BTICs
We and others previously showed that MYC is essential to the maintenance of BTIC self-
renewal and tumorigenic capacity25,26. MYC regulates enzymes involved in basic cellular 
metabolism, supporting a central role of MYC in metabolic reprogramming in cancers27. 
Using two independent shRNAs targeting MYC, we found that silencing MYC in BTICs 
significantly reduced mRNA levels of all six purine biosynthetic enzymes and protein levels 
of PRPS1, ADSL and GMPS (Fig. 4a and Supplementary Fig. 7a–g). Reciprocally, MYC 
overexpression in DGCs increased mRNA levels of all six purine biosynthetic enzymes and 
protein levels of PRPS1, ADSL and GMPS (Fig. 4b and Supplementary Fig. 7h–n). Linking 
these findings to the stem-like status of BTICs, knocking down MYC decreased mRNA level 
of precursor markers, including SOX2, NES and OLIG2, and elevated levels of 
differentiation markers, such as GFAP and MBPF (Supplementary Fig. 7o,p). Concordantly, 
overexpression of MYC in DGCs caused a two- to sevenfold increase in precursor markers, 
including SOX2, NES and OLIG2, and a decrease in mRNA levels of differentiation 
markers GFAP and MBP (Supplementary Fig. 7q,r). To assess the direct transcriptional 
effect of MYC on purine synthesis gene targets, we performed chromatin 
immunoprecipitation of MYC protein in two BTIC models, followed by reverse transcription 
and quantitative PCR (qRT-PCR) with primer sets designed for the promoter regions of 
PRPS1, PPAT, ADSL, ADSS, GMPS and IMPDH1. Compared to control IgG, MYC was 
more likely to occupy the promoter regions of genes involved in purine synthesis in BTICs 
(Fig. 4c,d).
We next examined the functional significance of MYC-regulated purine synthesis at the 
metabolic level. Knockdown of MYC in two BTIC models significantly decreased the 
absolute levels of IMP, AMP and GMP metabolites (Fig. 4e–g). Conversely, overexpressing 
MYC in two DGC models caused a dramatic increase in the absolute levels of IMP, AMP 
and GMP (Fig. 4h–j).
Metabolic crosstalk permits the integration of cell state and metabolic activity. 
Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) is a central signaling node that 
organizes the cellular response to the nutritional state, regulating survival and motility. To 
determine the function of PI3K in our findings, we treated three BTIC models with a PI3K 
inhibitor (LY294002), revealing attenuated activity of AKT, a downstream effector, and 
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reduced MYC levels, suggesting that PI3K is an upstream regulator of MYC (Fig. 4k). 
Further, acute glucose deprivation of 48 h reduced the activation of metabolic stress 
indicators, including AKT, mammalian target of rapamycin (mTOR) and ribosomal protein 
S6 kinase (S6K), as well as MYC levels, confirming the signaling crosstalk between key 
metabolic pathways (Fig. 4l). Our findings indicate that in BTICs, MYC directs carbon flow 
into the synthesis of purine metabolites by directly activating the transcription of purine 
synthesis genes.
AMP and GMP synthesis is required for BTIC maintenance
De novo purine synthesis pathway branches at the point of IMP: ADSS and ADSL catalyze 
the synthesis of AMP from IMP, while IMPDH and GMPS cooperate to synthesize GMP. To 
determine the functional significance of these two downstream synthetic pathways in BTIC 
maintenance, we assessed the roles of ADSL and GMPS expression and function in glioma 
(Figs. 5 and 6). Levels of ADSL and GMPS mRNA were significantly elevated in 542 
samples from the TCGA glioblastoma data set as compared to normal brain tissues (Figs. 5a 
and 6a)19,20. Expression levels of ADSL, GMPS and other purine synthesis genes did not 
significantly differ across molecular subtypes of glioblastoma, nor did known precursor 
markers, including OLIG2, MYC and SOX2, demonstrate a consistent pattern among 
subtypes, suggesting that these mechanisms may be shared across glioblastoma 
(Supplementary Fig. 8a–c). We interrogated the promoter regulation of purine synthetic 
genes across three matched pairs of BTICs and DGCs derived from three independent 
glioblastoma patients28, revealing that increased activation, as measured by H3K27ac peak 
levels, was greater in BTICs (Figs. 5b and 6b and Supplementary Fig. 8d,e). We next 
investigated mRNA levels for purine synthetic genes during serum-induced differentiation in 
three different BTIC models, demonstrating that differentiation suppressed the expression of 
purine synthetic genes in BTICs by approximately 80% (Figs. 5c and 6c and Supplementary 
Fig. 8g,h).
To determine the functional consequences of AMP and GMP synthesis in BTICs, we 
targeted the key enzymes in each synthetic pathway using a lentivirus-based vector to create 
independent, non-overlapping shRNAs targeting ADSL (shADSL-1 and shADSL-2) and 
GMPS (shGMPS-1 and shGMPS-2). The efficiency of ADSL and GMPS knockdown was 
confirmed at the protein level by immunoblotting (Supplementary Fig. 9a,b). Reducing the 
protein levels of either ADSL or GMPS significantly decreased BTIC growth and cell 
viability in two different models (Figs. 5d,e and 6d,e). The specificity of shRNA knockdown 
was confirmed by reconstituting ADSL and GMPS expression (Supplementary Fig. 9d,e), 
partially restoring the defect in cell viability of BTIC (Supplementary Fig. 9g,h,j,k). 
Knocking down ADSL or GMPS also reduced precursor markers SOX2, NES and OLIG2, 
and elevated differentiation markers GFAP and MBPF (Supplementary Fig. 9m,n,p,q). In 
contrast, purine synthesis is dispensable in DGCs, as targeting ADSL or GMPS expression 
had no effect on proliferation (Supplementary Fig. 10a,b).
Using in vitro limiting dilution assay, we demonstrated that knockdown of ADSL or GMPS 
significantly impaired self-renewal capacity, as measured by neurosphere formation (Figs. 5f 
and 6f). Sphere size, often considered a surrogate for proliferation, was significantly reduced 
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in BTICs expressing shRNAs targeting ADSL or GMPS compared to shCont (Figs. 5g,h and 
6g,h). We transplanted BTICs into the brains of immunocompromised mice to interrogate 
the effect of ADSL or GMPS in tumor initiation of BTICs in vivo. Mice bearing BTICs 
expressing shRNA targeting ADSL (shADSL-1 or shADSL-2) or GMPS (shGMPS-1 or 
shGMPS-2) demonstrated increased survival relative to shCont mice, establishing the role of 
ADSL and GMPS in maintaining tumorigenic capacity of BTICs in vivo (Fig. 5i,j and Fig. 
6i,j). To determine the mechanism of these in vivo effects, we examined the protein levels of 
Ki-67, cleaved caspase-3 and SOX2, as markers for proliferation, apoptosis and stemness, 
respectively, using immunohistochemistry in the transduced xenograft tumor specimens. 
Upon knockdown of ADSL or GMPS, cleaved caspase-3 increased, while Ki-67 and SOX2 
decreased (Supplementary Fig. 11a,b).
As cancer metabolism interacts with the immune system, we interrogated the roles of purine 
synthesis pathway in vivo using a murine glioma model in a syngeneic host. Specifically, we 
knocked down the expression of Adsl or Gmps in the mouse glioma 261 line (GL261) in an 
immunocompetent host. Knockdown efficiency was confirmed using qRT-PCR 
(Supplementary Fig. 12a,b). Intracranial implantation of GL261 cells expressing either 
control or gene-targeting shRNA was performed on MHC-matched C57BL/6J mice. 
Knocking down Adsl or Gmps increased the survival of immunocompetent mice bearing 
GL261 tumors (Supplementary Fig. 12d,e) and reduced tumor volume (Supplementary Fig. 
12g,h). These results establish nonredundant dependency of BTICs on the downstream 
components of de novo purine synthesis pathway, specifically AMP and GMP synthesis, as 
essential to maintaining BTIC proliferation, self-renewal and tumorigenicity.
PRPS1 is required for BTIC maintenance
PRPS1 catalyzes the first step of de novo purine synthesis by adding pyrophosphate onto 
R5P. Using gene expression data of glioblastoma and normal brain tissue from TCGA19,20, 
we found that the PRPS1 gene was overexpressed in glioblastoma (Fig. 7a). Consistently, 
the promoter regions of PRPS1 and PPAT were active in BTICs, as shown by accumulation 
of H3K27ac at these locations in BTICs as compared to matched DGCs (Fig. 7b and 
Supplementary Fig. 8f)28. Induction of BTIC differentiation in three patient-derived 
glioblastomas significantly decreased PRPS1 and PPAT mRNA levels (Fig. 7c and 
Supplementary Fig. 8i). These data led us to hypothesize that the gene encoding PRPS1 is 
critical to BTIC maintenance.
We then developed two non-overlapping shRNAs to knock down PRPS1, designated 
shPRPS1-1 and shPRPS1-2. The efficiency of PRPS1 knockdown was confirmed at the 
protein level by immunoblotting (Supplementary Fig. 9c). Targeting PRPS1 significantly 
decreased the growth and cell viability of BTICs (Fig. 7d,e). The specificity of shRNA 
knockdown was confirmed by reconstituting the expression of PRPS1 (Supplementary Fig. 
9f), which partially rescued the defect in cell viability of BTICs (Supplementary Fig. 9i,l). 
Knockdown of PRPS1 was also accompanied by a decrease in the precursor markers SOX2, 
NES and OLIG2 and elevation of the differentiation markers GFAP and MBP 
(Supplementary Fig. 9o,r). In contrast, targeting PRPS1 expression in matched DGCs did 
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not alter cellular proliferation (Supplementary Fig. 10c), again supporting dispensability of 
purine biosynthesis in differentiated tumor cells.
Using in vitro limiting dilution assay, we found that PRPS1 knockdown resulted in a more 
than threefold reduction in the frequency of sphere formation (Fig. 7f). Sphere size was also 
significantly reduced in BTICs expressing shRNAs targeting PRPS1 compared to those 
expressing shCont (Fig. 7g,h). To examine the effect of PRPS1 in maintaining tumorigenic 
potential of BTICs in vivo, we transplanted BTICs expressing PRPS1-directed shRNAs or 
shCont into the brains of immunocompromised mice. Animals bearing BTICs expressing 
shRNA targeting PRPS1 (shPRPS1-1 or shPRPS1-2) demonstrated significantly delayed 
tumor formation and increased survival relative to controls (Fig. 7i,j). The in vivo impact of 
targeting PRPS1 was also assayed by measuring the protein levels of Ki-67, cleaved 
caspase-3 and SOX2 as markers of proliferation, apoptosis and stemness, respectively, using 
immunohistochemistry in the xenograft specimens. Upon PRPS1 knockdown, cleaved 
caspase-3 increased, while Ki-67 and SOX2 decreased (Supplementary Fig. 11c). To 
determine a potential interaction with immune function, we first validated in vivo 
tumorigenesis experiments using murine GL261 glioma model in C57BL/6J syngeneic 
immunocompetent mice. Efficiency of PRPS1 knockdown was confirmed using qRT-PCR 
(Supplementary Fig. 12c). Intracranial implantation of GL261 cells expressing either control 
or gene-targeting shRNA was performed on MHC-matched C57BL/6J mice. Knocking 
down Prps1 significantly increased the survival of immunocompetent mice bearing GL261 
tumors (Supplementary Fig. 12f) and reduced tumor volume (Supplementary Fig. 12i). 
Taken together, our data support a role of the gene encoding purine synthesis enzyme PRPS1 
in sustaining BTIC phenotype, as measured by proliferation, self-renewal and 
tumorigenicity.
Overexpression of de novo purine synthesis pathway genes is associated with poor 
prognosis in glioma patients
To generalize our findings of purine synthesis pathway dependence to glioma patients, we 
investigated glioma databases to examine gene expression of enzymes involved in purine 
synthesis19,20. Mapping purine synthetic genes across gliomas of all grades, purine synthetic 
genes were strongly enriched in non-CpG island methylator phenotype (non-CIMP) grade 
III and IV gliomas, without correlation to specific genetic lesions beyond IDH wild-type 
status (Supplementary Fig. 13a). These results were concordant with our functional data, as 
we selected BTIC models to represent each of the major TCGA transcriptional groups (data 
not shown). To interrogate the functional linkage between purine biology and tumor 
processes in silico, we performed a gene set enrichment analysis with a purine metabolic 
signature, finding cell cycle regulation as the dominant process, with linkage to mRNA 
metabolism, Wnt signaling and antigen processing (Supplementary Fig. 13b). Cell cycle 
progression would be expected to depend on purine availability, but we previously reported 
that BTICs and DGCs display similar cell cycle profiles29, suggesting that BTICs 
preferentially depend on de novo purine synthesis.
To determine the clinical relevance of purine biosynthesis, we interrogated the linkage 
between purine synthesis enzymes and patient outcome. Increased levels of four genes from 
Wang et al. Page 9
Nat Neurosci. Author manuscript; available in PMC 2018 June 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
de novo purine synthesis pathway, ADSL, ADSS, IMPDH1 and PPAT, were associated with 
poor prognosis in glioblastoma patients (Fig. 8a). PPAT is the second enzyme on the main 
branch that synthesizes IMP from R5P. Higher PPAT gene expression is associated with 
shorter survival in glioblastoma (P = 0.0111). Through retrospective analysis of the TCGA 
data set, increased expression of IMPDH1 (on the sub-branch synthesizing GMP from IMP) 
and both ADSL and ADSS (on the sub-branch synthesizing AMP from IMP) were 
correlated with worse prognosis in glioblastoma patients (IMPDH1: P = 0.0325; ADSL: P = 
0.0056; ADSS: P = 0.0376).
To further assess the significance of purine synthesis pathway expression in brain tumor 
patients, we generated Kaplan-Meier survival curves in independent glioma data sets30-32, 
which include both low-grade glioma and glioblastoma specimens. Overexpression of PPAT 
was associated with significantly shorter survival among glioma patients in both the Freije 
(P = 0.0025) and Phillips (P = 0.0069) data sets (Fig. 8b,c). Higher expression of two other 
purine synthesis genes, IMPDH1 (P = 0.0066) and ADSS (P = 0.0004), was also correlated 
with worse survival in the Freije and Phillips data sets, respectively (Fig. 8b,c). 
Comprehensive analysis of each of the six de novo purine biosynthesis enzymes supports a 
general link between activation of purine metabolism and poor clinical outcome 
(Supplementary Fig. 13c–r).
DISCUSSION
Improved outcomes for brain cancer patients will require new therapeutic models. Using 
comprehensive metabolomic and genomic approaches in patient-derived glioma models, we 
found that BTICs activate de novo purine synthesis to maintain self-renewal, proliferation 
and tumor forming capacity (modeled in Supplementary Fig. 14). Purine synthesis starts 
with ribose 5-phosphate (R5P), the sugar backbone of the nucleotide, which is typically 
generated in normal cells by diverting glucose-6-phosphate into the oxidative pentose 
phosphate pathway (PPP)33. An important byproduct generated by the PPP is NADPH, 
which donates hydrogen in reductive anabolism, including lipid synthesis and cellular redox 
balance through the transformation of glutathione34. Cancer cells synthesize R5P through an 
alternative, nonoxidative branch of the PPP catalyzed by the concerted actions of 
transketolase and transaldolase35,36. This metabolic reprogramming facilitates production of 
purine nucleotides without creating excessive NADPH and perturbing redox balance in 
cancer cells.
Recent analysis of cell mass formation demonstrated that glucose, together with glutamine 
and serine, significantly contributed to the carbon sources of DNA and RNA, both of which 
are downstream from purine synthesis37. Carbon flow from glucose and serine in mouse 
embryonic fibroblasts into de novo purine synthesis through the mitochondrial 
tetrahydrofolate cycle is regulated by mTORC1 and ATF4 (ref. 38). In contrast, we did not 
observe a consistent activation of the PPP in BTICs (data not shown). Instead, BTICs 
upregulate the enzymes involved in purine synthesis (including PRPS1 and PPAT on the 
common branch to synthesize IMP, ADSL and ADSS on one side branch to synthesize 
AMP; and GMPS and IMPDH1 on the other side branch to synthesize GMP) to efficiently 
channel glucose-derived R5P into the production of basic purine nucleotides, including IMP, 
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AMP and GMP. AMP and GMP serve as critical building blocks for DNA replication and 
for RNA production to support protein synthesis, collectively sustaining BTIC self-renewal 
and proliferative capacity. Further, cAMP and cGMP, synthesized from purine nucleotides 
through adenylate cyclase and guanylate cyclase, function as second messengers. Genetic 
perturbation of key enzymes, including ADSL, GMPS and PRPS1, significantly decreased 
the BTIC maintenance in both immunodeficient and immunocompetent mouse models. Our 
findings are consistent with a recent report of 13C-based glucose carbon tracing experiments 
in non-small-cell lung cancer patients during surgery, which showed heterogeneous glucose 
metabolism within these tumors39. Glucose was found to be the dominant fuel for energy 
and anabolism in the less perfused regions39, supporting the link between nutrient restriction 
and cellular reprogramming13.
Metabolic reprogramming in cancer cells is often executed through coordinated regulation of 
enzymes for a whole synthetic pathway, in contrast to the activation or inhibition of a single 
rate-limiting step enzyme found in untransformed cells33. By examining the TCGA data set 
and testing in patient-derived xenograft models, we found that the expression of purine 
synthesis enzymes in BTICs is regulated in a concerted manner in glioblastoma, indicating a 
potential upstream transcriptional regulator. In glioblastoma, we previously demonstrated 
that MYC is essential to the maintenance of the BTIC phenotype25. Here we interrogated the 
downstream targets of MYC in BTIC, showing that MYC directly activates the transcription 
of all six essential genes in the purine biosynthetic pathway. De novo purine synthesis is 
regulated by several mechanisms beyond MYC in cancer cells33,36. The PI3K–AKT 
signaling pathway promotes metabolic reprogramming in tumors and can modulate carbon 
flow into purine synthesis40. We previously showed that inhibition of this pathway is a 
specific therapeutic approach in targeting BTICs compared to differentiated progeny41, 
further highlighting a potential link between the PI3K–AKT pathway and purine synthesis in 
promoting tumor initiating phenotype. In the current study, we demonstrate that the PI3K–
AKT pathway regulates MYC protein level, which in turn modulate the expression of purine 
synthesis enzymes in BTICs.
The preferential requirement of de novo purine synthesis in BTICs can be exploited 
therapeutically for glioblastoma treatment42. Inhibitors blocking purine synthesis could be 
used as an adjuvant therapy specifically targeting BTICs in combination with current 
regimens of radiation, temozolomide and bevacizumab. Two IMPDH inhibitors are already 
widely used in the clinic. Mycophenolate mofetil (CellCept) and mycophenolate sodium 
(Myfortic) are both potent immunosuppressants used in organ transplant and autoimmune 
diseases43,44. The active component, mycophenolic acid, inhibits IMPDH at nanomolar 
range by acting as the nicotinamide portion of the cofactor nicotinamide adenine 
dinucleotide45. Ribavirin, a broad-spectrum antiviral agent active against both DNA and 
RNA viruses, inhibits the activity of human IMPDH, which depletes cellular pool of GTP 
and dGTP to block viral replication46,47. Newer agents with greater potency inhibiting 
IMPDH, such as VX-497, are under clinical investigation as antivirals48. In addition to 
directly targeting the purine synthesis pathway, inhibitors to upstream regulatory 
mechanisms are also potential choices for anti-BTIC therapy. For example, BKM-120, a 
pan-class I PI3K inhibitor capable of penetrating the blood-brain barrier, is undergoing 
phase II clinical study for recurrent glioblastoma (NCT01339052)49,50. Taken together, the 
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results of our study demonstrate the distinct requirement of de novo purine synthesis in 
BTIC maintenance and survival, an intratumoral population difficult to eradicate with 
current treatment strategies. Developing therapeutics against purine synthesis could 
therefore synergize with radiation and chemotherapy to achieve improved management of 
glioblastoma.
ONLINE METHODS
Isolation and culture of cells
Glioblastoma tissues were obtained from excess surgical materials from patients at the 
Cleveland Clinic after neuropathology review with appropriate consent, in accordance with 
an IRB-approved protocol. To prevent culture-induced drift, patient-derived xenografts were 
generated and maintained as a recurrent source of tumor cells for study. Immediately upon 
xenograft removal, a papain dissociation system (Worthington Biochemical) was used to 
dissociate tumors according to the manufacturer’s instructions. Cells were then cultured in 
Neurobasal medium (Life Technologies) supplemented with B27, l-glutamine, sodium 
pyruvate, 10 ng/ml basic fibroblast growth factor and 10 ng/ml epidermal growth factor 
(R&D Systems) for at least 6 h to recover expression of surface antigens. No marker is 
uniformly informative for BTICs, so we use a combination of functional criteria to validate 
BTICs. Both BTICs and DGCs were derived immediately after dissociation or after transient 
xenograft passage in immunocompromised mice using prospective sorting followed by 
assays to confirm stem cell marker expression, sphere formation and secondary tumor 
initiation. For experiments using matched BTIC and DGC cultures, we segregated AC133 
marker-positive and marker-negative populations using CD133/1 antibody-conjugated 
magnetic beads (Miltenyi Biotech, Auburn, CA), as previously described4,13. The BTIC 
phenotype was validated by stem cell marker expression (OLIG2 and SOX2), functional 
assays of self-renewal (serial neurosphere passage), and tumor propagation using in vivo 
limiting dilution.
Plasmids and lentiviral transduction
Lentiviral clones expressing shRNAs directed against human ADSL (TRCN0000078271, 
TRCN0000078272), human GMPS (TRCN0000045939, TRCN0000045940), human 
PRPS1 (TRCN0000010123, TRCN0000010125), murine Adsl (TRCN0000120128, 
TRCN0000339620), murine Gmps (TRCN0000251162, TRCN0000251160), murine Prps1 
(TRCN0000024886, TRCN0000024888), human MYC (TRCN0000039640, 
TRCN0000039642), human GLUT3 (TRCN0000043616, TRCN0000043615) or a control 
shRNA that has no targets in either human or mouse genome (shCont: SHC002) were 
obtained from Sigma-Aldrich (St. Louis, MO). shRNAs with non-overlapping sequences 
that had the best relative knockdown efficiency were used for all experiments. Lentiviral 
overexpression plasmid for human MYC was generated by cloning the ORF with the N-
terminal Flag into the pCDH-MCS-T2A-Puro-MSCV vector (System Biosciences)51. 
Lentiviral particles were generated in 293FT cells in Neurobasal complete medium (Life 
Technologies) with cotransfection with the packaging vectors pCMV-dR8.2 dvpr and pCI-
VSVG (Addgene) using standard calcium phosphate transfection.
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Metabolic analysis of BTIC using mass spectrometry
For metabolomics screening experiments, pairs of BTIC and DGC cells were incubated with 
medium in which all glucose was replaced with [13C6]glucose (Cambridge Isotope 
Laboratories #CLM-1396-1) for 24 h before harvesting. Cell lysates were then subjected to 
untargeted mass spectrometry. For nitrogen tracing experiments, BTICs were incubated with 
medium in which all glutamine was replaced with 13N2-glutamine (Cambridge Isotope 
Laboratories #NLM-1328-PK) for 24 h before harvesting. For targeted mass spectrometry of 
purine synthesis intermediates, pure samples of AMP, GMP and IMP were purchased from 
Sigma-Aldrich, and the internal standard [13C5]AMP was purchased from Toronto Research 
Chemical, Inc. All solvents used were HPLC grade from Fisher Scientific. Cells were dried 
and then extracts of cell lysates were reconstituted with 180 μl water, 20 μl of internal 
standard (50 μM [13C5]AMP). After vortexing for 60 s, the reconstituted sample was 
centrifuged for 60 s using a Beckman Coulter centrifuge (Microfuge 22R, Brea, CA) at 
12,000 r.p.m. at 4 °C for 10 min. After centrifugation, 140 μl of supernatant was transferred 
into a vial for analysis by LC/MS/MS. The Waters 2690 Module (Waters, Corp., Franklin, 
MA) HPLC system was directly interfaced with a triple-quadrupole mass spectrometer 
(Quattro Ultima, Waters Inc., Beverly, MA) using electrospray ionization in negative mode 
and multiple reaction monitoring. Peak areas in the LC/MS/MS chromatogram for each 
analyte and internal standard were generated using QuanLynx attached to Masslynx V4.1 
software. Internal standard calibration curves were used to quantify the three 
monophosphate nucleotides in cell lysates.
Proliferation and neurosphere formation assay
Cell proliferation was measured using Cell-Titer Glow (Promega, Madison, WI). All data 
were normalized to day 0 and are presented as mean ± s.e.m. Neurosphere formation was 
measured by in vitro limiting dilution, as previously described13,52. Briefly, decreasing 
numbers of cells per well (50, 20, 10, 5 and 1) were plated into 96-well plates. Seven days 
after plating, the presence and number of neurospheres in each well were recorded. Extreme 
limiting dilution analysis was performed using software available at http://
bioinf.wehi.edu.au/software/elda, as previously described13,52.
Quantitative RT-PCR
Total cellular RNA was isolated using Trizol reagent (Sigma-Aldrich), followed by reverse 
transcription into cDNA using the qScript cDNA Synthesis Kit (Quanta BioSciences). Real-
time PCR was performed using an Applied Biosystems 7900HT cycler using SYBR-Green 
PCR Master Mix (Thermo Fisher Scientific). Sequences for gene-specific primer sets were 
as follows: human PRPS1 forward 5′-ATCTTCTCCGGTCCTGCTATT-3′ and reverse 5′-
TGGTGACTACTACTGCCTCAAA-3′; human PPAT forward 5′-
GATGGGAGTTCGGTGCCAA-3′ and reverse 5′-CAACGAAGGGC 
TGACAATTTTC-3′; human ADSL forward 5′-GCTGGAGGCGATCATGGTTC-3′ and 
reverse 5′-TGATAGGCAAACCCAATGTCTG-3′; human ADSS forward 5′-
TGGGTATGCCACCTCAAAATG-3′ and reverse 5′-GCTCT 
GTAGGAAAGGCACCAATA-3′; human GMPS forward 5′-ATGGCTCTGT 
GCAACGGAG-3′ and reverse 5′-CCTCACTCTTCGGTCTATGACT-3′; human IMPDH1 
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forward 5′-CAGCAGGTGTGACGTTGAAAG-3′ and reverse 5′-
AGCTCATCGCAATCATTGACG-3′; murine Prps1 forward 5′-
ACTTATCCCAGAAAATCGCTGAC-3′ and reverse 5′-CCACACCCACTTTGAA 
CAATGTA-3′; murine Adsl forward 5′-AAAGCTGCGGGCATTATTCAT-3′ and reverse 
5′-GCACGATCCTTAGCAAAGTCG-3′; murine Gmps forward 5′-
GCCCTGTGCAACGGAGATT-3′ and reverse 5′-GCTCCTTCGTAATGGTGAGA AC-3′; 
human MYC forward 5′-GGCTCCTGGCAAAAGGTCA-3′ and reverse 5′-
CTGCGTAGTTGTGCTGATGTH3′; and human 18S RNA forward 5′-
AACCCGTTGAACCCCATT-3′ and reverse 5′-CCATCCAATCGGTAGTAGCG-3′.
Western blotting
Cells were collected and lysed in RIPA buffer (50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 
0.5% NP-40; 50 mM NaF with protease inhibitors) and incubated on ice for 30 min. Lysates 
were centrifuged at 20,817g at 4 °C for 10 min and supernatant was collected. Protein 
concentration was determined using the Bradford assay (Bio-Rad Laboratories, Hercules, 
CA). Equal amounts of protein samples were mixed with SDS Laemmli loading buffer, 
boiled and electrophoresed using NuPAGE Bis-Tris Gels (Life Technologies), then 
transferred onto PVDF membranes (Millipore). Blocking was performed for 45 min using 
TBST supplemented with 5% non-fat dry milk and blotting performed with primary 
antibodies at 4 °C for 16 h. The following antibodies were used: ADSL (Abcam 
#ab154182), GMPS (Cell Signaling #14602), PRPS1 (Abcam #ab154721), MYC (N-262, 
Santa Cruz #sc-764), total AKT (Cell Signaling #4691), phospho-AKT (S473, Cell 
Signaling #9271), total S6 (Cell Signaling #2317), phospho-S6 (235/236, Cell Signaling 
#4858), phospho-S6 (240/242, Cell Signaling #5364), total p70 S6K (Cell Signaling #2708), 
phospho-p70 S6K (Cell Signaling #9234) and α-tubulin (Sigma #T6074). All antibody 
validation information is available in the product’s manual. For western blotting, the dilution 
was 1:500 for MYC antibody and 1:1,000 for all other antibodies.
Immunohistochemistry
Immunohistochemistry experiments were performed using specimens from xenografted 
tumors in mouse model. The following primary antibodies were used: cleaved caspase 3 
(Cell Signaling #9664, 1:300), SOX2 (R&D #MAB2018, 1:200) and Ki-67 (DAKO 
#M7240, 1:300). Biotinylated secondary antibodies were used together with the Vectastain 
ABC kit and the DAB kit (Vector Laboratories) per manufacturer’s instructions. All 
antibody validation information is available in the product’s manual.
Chromatin immunoprecipitation (ChIP) assay
4 × 106 cells per condition were collected, and ChIP was performed using the EZ-ChIP 
chromatin immunoprecipitation kit (EMD Millipore #17-371) following the manufacturer’s 
protocol. Briefly, 5 μg MYC antibody (N-262, Santa Cruz #sc-764) or rabbit IgG was used 
for the immunoprecipitation of the DNA-protein immunocomplexes. Crosslinking was 
reversed by heating for 6 h at 65 °C, followed by digestion with proteinase K. The purified 
DNA was subjected to quantitative PCR using the following primer sets: human PRPS1 
forward 5′-GAGGGTGCAGCTCTGTGACT-3′ and reverse 5′-
CAGCCACTATCTATTGGGTC-3′; human PPAT forward 5′-TGCG 
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GTACATCCAGCTGCGT-3′ and reverse 5′-TGGTTGGTGCTTACACCT TG-3′; human 
ADSL forward 5′-TAGCGACAGGTATAAATTCC-3′ and reverse 5′-
TCTCCTGCCCTTGCTTTCCT-3′; human ADSS forward 5′-TCT 
CGCTTTCAAACTGGA-3′ and reverse 5′-TGTTTGTACTGCGAAATTCC-3′; human 
GMPS forward 5′-CTGCGGAGGGTATCTGAG-3′ and reverse 5′-
CGCCGAATGGAGCAACAG-3′; human IMPDH1 forward 5′-GTCT 
GCATCCCCCAACCAAAG-3′ and reverse 5′-ACTGCTGCAGGCCGGCTAC-3′.
For ChIP-seq experiments, 5–10 mg of flash-frozen BTIC or DGC cells was subjected to 
ChIP using 5 mg of H3K27ac antibody per specimen (Abcam-AB4729). Enriched DNA was 
quantified using Picogreen (Invitrogen) and ChIP libraries were amplified and barcoded 
using the Thruplex DNA-seq library preparation kit (Rubicon Genomics) according to 
manufacturer recommendations. Following library amplification, DNA fragments of less 
than 1 kb were size selected using a 1.0% agarose gel, assessed using Bioanalyzer (Agilent 
Technologies) and sequenced using Illumina Hi-Seq 2000 100-bp single-end sequencing.
In vivo tumorigenesis
BTICs derived from human glioblastoma specimens were transduced with lentiviral vectors 
expressing shRNA targeting ADSL, GMPS or PRPS1, or expressing a non-targeting control 
shRNA (shCont) for the knockdown experiment. 36 h after infection, viable cells were 
counted and engrafted intracranially into NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, The 
Jackson Laboratory, Bar Harbor, ME) mice. For the immunocompetent model, murine 
glioma 261 (GL261) cells were transduced with lentiviral vectors expressing shRNA 
targeting murine Adsl, Gmps or Prps1, or expressing shCont. 36 h after infection, viable 
cells were counted and engrafted intracranially into syngeneic host stain C57BL/6J (The 
Jackson Laboratory). All mice experiments were performed under an animal protocol 
approved the Institutional Animal Care and Use Committee of the Cleveland Clinic. Healthy 
female mice of NSG or C57BL/6J background, 4–6 weeks old, were randomly selected and 
used in this study for intracranial injection. Animals were maintained until neurological 
signs were apparent, at which point they were sacrificed. Brains were collected and fixed in 
4% formaldehyde, cryopreserved in 30% sucrose and then cryosectioned. Sections were 
stained with hematoxylin and eosin for histological analysis. In parallel survival 
experiments, animals were monitored until they developed neurological signs.
Statistical analysis
No statistical methods were used to predetermine sample sizes, but our sample sizes are 
similar to those reported in previous publications4,13. A two-sided unpaired Student’s t-test 
was used to assess differences between groups. Data distribution was assumed to be normal, 
but this was not formally tested. Kaplan-Meier survival curves were generated using Prism 
software and a log-rank test was performed to assess statistical significance between groups. 
For all figures presented in box-and-whisker format, the center line represents the median 
and the lower and upper limits of the box represent the 25th and 75th percentiles. The 
maximum and minimum are connected to the center box through the vertical lines 
(whiskers). No animals or data points were excluded from the analyses for any reason. 
Blinding and randomization were performed in all experiments. Correlation between gene 
Wang et al. Page 15
Nat Neurosci. Author manuscript; available in PMC 2018 June 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
expression and patient survival was performed through analysis of TCGA, Freije, Phillips 
and REMBRANDT brain tumor data sets, downloaded from the TCGA data portal or NCBI 
GEO database. High and low expression groups were defined as above and below the mean 
expression level, respectively. A Supplementary Methods Checklist is available.
Data and code availability
The exome sequencing data are available from the NCBI SRA Database (accession code 
SRR5275896). The ChIP-seq data are available from Gene Expression Omnibus (accession 
code GSE95216). The data and analysis routines that support the findings of this study are 
available from the corresponding author upon reasonable request.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
BTICs upregulate de novo purine synthesis. (a,b) Waterfall plots of non-targeted small 
molecule mass spectrometry profiling differential levels of metabolites in BTICs and 
matched DGCs from two patient-derived glioblastoma specimens, T387 and T4121, treated 
with [13C6]glucose. Each identified small molecule was scored by its relative level of 13C 
incorporation in BTICs compared to that in DGCs. (c–e) Targeted mass spectrometry 
showed elevated levels of purine metabolites (IMP, AMP and GMP) using cell lysates of 
BTICs and matched DGCs from five patient-derived glioblastoma specimens (T3691, T387, 
T4121, TIN528 and T3565). The relative levels of these three metabolites normalized to 
those of DGCs are shown. Center line represents the median, lower and upper limits of the 
box represent the 25th and 75th percentiles, and whiskers show maximum and minimum. 
Two-tailed unpaired Student’s t-test; **P < 0.0001; n = 4 independent experiments per 
group. (IMP: T3691, t(6) = 37.688; T387, t(6) = 20.709; T4121, t(6) = 21.137; TIN528, t(6) 
= 32.948; T3565, t(6) = 18.947. AMP: T3691, t(6) = 37.525; T387, t(6) = 18.385; T4121, 
t(6) = 24.088; TIN528, t(6) = 46.790; T3565, t(6) = 17.106. GMP: T3691, t(6) = 29.267; 
T387, t(6) = 9.347; T4121, t(6) = 16.995; TIN528, t(6) = 20.899; T3565, t(6) = 11.145.) (f) 
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Pairwise correlation analysis of six representative genes in purine synthesis pathway. Plots 
indicate gene expression data from TCGA glioblastoma patients for PRPS1, PPAT, ADSS, 
ADSL, GMPS and IMPDH1. Correlation coefficient (R) values are shown. (g) BTICs 
upregulate protein levels of purine synthesis enzymes (PRPS1, GMPS and ADSL) relative to 
DGCs across human glioblastoma specimens T3691, T387 and 4121. Full-length western 
blots are presented in Supplementary Figure 15. (h) Sensitivity of four patient-derived BTIC 
models (T387, T3565, T3691 and T4121) to the purine synthesis inhibitor mycophenolic 
acid. (i) Sensitivity of four patient-derived BTIC models (T387, T3565, T3691 and T4121) 
to the purine synthesis inhibitor mycophenolate mofetil. (j) Sensitivity of four patient-
derived BTIC models (T387, T3565, T3691 and T4121) to the purine synthesis inhibitor 
ribavirin. Data are presented as mean ± s.e.m.
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Figure 2. 
Genomic profiling reveals specific upregulation of de novo purine synthesis pathway in 
BTICs. (a,b) H3K27ac ChIP-seq coverage plots that illustrate (a) DGC-specific and (b) 
BTIC-specific enhancers in T4121 glioma cells. Heat maps are shown to depict H3K27ac 
signal, normalized to read depth, for ±5 kb surrounding enhancer peaks. Color scale 
indicates reads per kilobase per million mapped reads (RPKM). The y axis is also 
normalized H3K27ac read depth (RPKM). (c) Enrichment analysis of all metabolic 
pathways in BTICs (red) versus DGCs (orange) derived from differential H3K27 acetylation 
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in the T4121 glioblastoma cell line. Pathway enrichment was assessed using single-sample 
gene set enrichment analysis comparing pathway enrichment scores between T4121 BTICs 
and DGCs. NAD, nicotinamide adenine dinucleotide; ABC, ATP-binding cassette. (d–g) 
H3K27ac ChIP-seq analysis of matched T4121 BTICs and DGCs for focused metabolic 
pathways. Transcriptional start sites (TSS) for selected metabolic genes were mapped for (d) 
glutathione, (e) glycolysis, (f) pentose phosphate and (g) purine metabolism.
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Figure 3. 
Glycolytic activity modulates de novo purine synthesis in BTICs. (a–c) Effect of standard 
(4.5 g/L) and restricted (0.45 g/L) glucose conditions on mRNA levels of six purine 
synthesis pathway genes (PRPS1, PPAT, ADSL, ADSS, GMPS and IMPDH1) in T3691, 
T387 and T4121 BTICs. Two-tailed unpaired Student’s t-test; *P < 0.05; **P < 0.01; n = 3 
independent experiments per group. Data are presented as median ± s.e.m. (T3691 (a): 
PRPS1, P = 0.0002, t(4) = 13.322; PPAT, P < 0.0001, t(4) = 53.492; ADSL, P < 0.0001, t(4) 
= 32.615; ADSS, P < 0.0001, t(4) = 42.225; GMPS, P < 0.0001, t(4) = 40.682; IMPDH1, P 
= 0.0021, t(4) = 7.025. T387 (b): PRPS1, P = 0.0066, t(4) = 9.452; PPAT, P = 0.0074, t(4) = 
8.557; ADSL, P = 0.0320, t(4) = 4.487; ADSS, P = 0.0160, t(4) = 5.083; GMPS, P = 0.0038, 
t(4) = 8.158; IMPDH1, P = 0.0002, t(4) = 12.822. T4121 (c): PRPS1, P = 0.0015, t(4) = 
8.907; PPAT, P = 0.0020, t(4) = 11.505; ADSL, P = 0.0100, t(4) = 7.569; ADSS, P = 0.0001, 
t(4) = 10.662; GMPS, P = 0.0056, t(4) = 6.886; IMPDH1, P = 0.0270, t(4) = 4.463.) (d) 
Protein levels of PRPS1, ADSL and GMPS under restricted glucose conditions (0.45 g/L) 
compared to standard conditions (4.5 g/L). (e) Levels of purine metabolites (IMP, AMP and 
GMP) under standard (4.5 g/L) and restricted (0.45 g/L) glucose conditions in T3691, T387 
and T4121 BTICs. Two-tailed unpaired Student’s t-test; **P < 0.01; n = 4 independent 
experiments per group. (IMP: T3691, P < 0.0001, t(6) = 19.866; T387, P < 0.0001, t(6) = 
42.874; T4121, P < 0.0001, t(6) = 39.350. AMP: T3691, P < 0.0001, t(6) = 22.970; T387, P 
< 0.0001, t(6) = 34.374; T4121, P < 0.0001, t(6) = 34.989. GMP: T3691, P < 0.0001, t(6) = 
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24.155; T387, P < 0.0001, t(6) = 27.871; T4121, P < 0.0001, t(6) = 41.121.) (f–h) Treatment 
with 2-DG decreased the mRNA levels of six purine synthesis pathway genes (PRPS1, 
PPAT, ADSL, ADSS, GMPS and IMPDH1) in T3691, T387 and T4121 BTICs. Two-tailed 
unpaired Student’s t-test; **P < 0.01; n = 3 independent experiments per group. Data are 
presented as median ± s.e.m. (T3691: PRPS1, P < 0.0001, t(4) = 38.981; PPAT, P < 0.0001, 
t(4) = 45.247; ADSL, P < 0.0001, t(4) = 36.126; ADSS, P < 0.0001, t(4) = 20.815; GMPS, P 
= 0.0001, t(4) = 15.147; IMPDH1, P = 0.0002, t(4) = 13.439. T387: PRPS1, P < 0.0001, t(4) 
= 97.734; PPAT, P < 0.0001, t(4) = 26.615; ADSL, P = 0.0036, t(4) = 6.118; ADSS, P = 
0.0002, t(4) = 12.486; GMPS, P < 0.0001, t(4) = 22.360; IMPDH1, P < 0.0001, t(4) = 
20.446. T4121: PRPS1, P < 0.0001, t(4) = 50.270; PPAT, P < 0.0001, t(4) = 19.526; ADSL, 
P = 0.0051, t(4) = 5.572; ADSS, P = 0.0021, t(4) = 7.070; GMPS, P = 0.0002, t(4) = 13.103; 
IMPDH1, P = 0.0055, t(4) = 5.452. (i) Immunoblot analysis highlighting decreased protein 
levels of PRPS1, ADSL and GMPS under 2-DG treatment (0.45 g/L) compared to control. 
(j) Targeted mass spectrometry to examine the level of purine metabolites (IMP, AMP and 
GMP) under 2-DG or control treatment in T3691, T387 and T4121 BTICs. Two-tailed 
unpaired Student’s t-test; **P < 0.0001; n = 4 independent experiments per group. (IMP: 
T3691, t(6) = 26.947; T387, t(6) = 67.355; T4121, t(6) = 22.435. AMP: T3691, t(6) = 
29.278; T387, t(6) = 47.672; T4121, t(6) = 20.124. GMP: T3691, t(6) = 28.602; T387, t(6) = 
32.596; T4121, t(6) = 31.558.) (k) Immunoblot analysis highlighting decreased protein 
levels of PRPS1, ADSL and GMPS after shRNA-mediated GLUT3 knockdown. All full-
length western blots are presented in Supplementary Figure 15. In e,j, center line represents 
the median, lower and upper limits of the box represent the 25th and 75th percentiles, and 
whiskers show maximum and minimum.
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Figure 4. 
Transcription factor MYC regulates de novo purine synthesis pathway enzymes in BTICs. 
(a) Knockdown of MYC in BTICs using two independent shRNAs decreased the protein 
levels of PRPS1 and GMPS in T387 and T4121 BTICs. Tubulin was used as a loading 
control. (b) Overexpression of exogenous MYC upregulated protein levels of purine 
synthesis enzymes PRPS1, ADSL and GMPS in T387 and T4121 DGCs. (c,d) Transcription 
factor MYC bound directly to promoter regions of enzymes in purine synthesis pathway in 
(c) T387 and (d) T4121 BTICs. Two-tailed unpaired Student’s t-test; *P < 0.05; **P < 0.01; 
n = 3 independent experiments per group. Data are presented as median ± s.e.m. (T387: 
PRPS1, P = 0.0075, t(4) = 5.379; PPAT, P = 0.0078, t(4) = 4.904; ADSL, P = 0.0072, t(4) = 
6.054; ADSS, P = 0.0008, t(4) = 12.225; GMPS, P = 0.0009, t(4) = 8.949; IMPDH1, P = 
0.0200, t(4) = 3.654. T4121: PRPS1, P = 0.0005, t(4) = 10.270; PPAT, P = 0.0026, t(4) = 
7.175; ADSL, P < 0.0001, t(4) = 25.230; ADSS, P = 0.0260, t(4) = 3.427; GMPS, P = 
0.0017, t(4) = 7.917; IMPDH1, P = 0.0086, t(4) = 6.138.) (e–g) Knockdown of MYC using 
two independent shRNAs decreased the level of purine metabolites in BTICs. Mass 
spectrometry was used to assess the levels of (e) IMP, (f) AMP and (g) GMP in BTICs. Two-
tailed unpaired Student’s t-test; **P < 0.01; n = 4 independent experiments per group. (IMP: 
T387, shRNA-1, P < 0.0001, t(6) = 24.084; shRNA-2, P < 0.0001, t(6) = 24.802; T4121, 
shRNA-1, P = 0.0008, t(6) = 4.653; shRNA-2, P = 0.0006, t(6) = 4.890. AMP: T387, 
shRNA-1, P < 0.0001, t(6) = 30.416; shRNA-2, P < 0.0001, t(6) = 31.323; T4121, shRNA-1, 
P = 0.0069, t(6) = 3.143; shRNA-2, P = 0.0057, t(6) = 3.272. GMP: T387, shRNA-1, P < 
0.0001, t(6) = 20.868; shRNA-2, P < 0.0001, t(6) = 21.045; T4121, shRNA-1, P = 0.0003, 
t(6) = 5.393; shRNA-2, P = 0.0002, t(6) = 5.687.) (h–j) Overexpression of exogenous MYC 
upregulates the level of purine metabolites of (h) IMP, (i) AMP and (j) GMP in T387 and 
T4121 DGCs. Two-tailed unpaired Student’s t-test; **P < 0.0001; n = 4 independent 
experiments per group. (IMP: T387, t(6) = 11.949; T4121, t(6) = 15.436. AMP: T387, t(6) = 
17.874; T4121, t(6) = 12.641. GMP: T387, t(6) = 23.280; T4121, t(6) = 45.919.) (k) Effect 
of PI3K inhibitor LY-294002 (5 μM for 48 h) on the levels of phospho-AKT (p-AKT), total 
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AKT and MYC in three BTIC models (T3691, T387 and T4121). (l) Effect of restricted 
glucose conditions (0.45 g/L) and standard conditions (4.5 g/L) for 48 h on the levels of 
MYC, phospho-AKT, total AKT, phospho-p70 S6 kinase (p-P70S6K) (Thr389), total p70 S6 
kinase (P70S6K), S6 phosphorylated on Ser235 or Ser236 (p-S6(235/236)), S6 
phosphorylated on Ser240 or Ser244 (p-S6(240/244)) and total S6 in three BTIC models 
(T3691, T387 and T4121). All full-length western blots are presented in Supplementary 
Figure 15. In e–j, center line represents the median, lower and upper limits of the box 
represent the 25th and 75th percentiles, and whiskers show maximum and minimum.
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Figure 5. 
ADSL regulates BTIC growth and self-renewal. (a) Microarray-based gene expression levels 
of ADSL from 542 glioblastoma (GBM) specimens and 10 different specimens of normal 
brain tissues. Expression data were derived from the TCGA glioblastoma data set (P < 
0.0001, t(550) = 6.095, two-tailed unpaired Student’s t-test). (b) H3K27ac ChIP-seq 
enrichment plot centered at the gene locus for ADSL. Enrichment is shown for three 
matched pairs of DGCs and BTICs from patient-derived glioblastoma specimens. H3K27ac 
ChIP-seq data were downloaded from NCBI Gene Expression Omnibus GSE54047. (c) qRT-
PCR quantification of ADSL mRNA in BTICs and DGCs. BTICs derived from three 
primary human glioblastoma specimens (T3691, T387, T4121) were treated with serum to 
induce differentiation over a course of 2, 4 or 6 d. Two-tailed unpaired Student’s t-test; **P 
< 0.01; n = 3 independent experiments per group. Data are presented as median ± s.e.m. 
(T3691: 2 d, P = 0.0014, t(4) = 7.967; 4 d, P = 0.0011; t(4) = 8.381; 6 d, P = 0.0007, t(4) = 
9.534. T387: 2 d, P = 0.0004, t(4) = 11.190; 4 d, P = 0.0003, t(4) = 11.454; 6 d, P = 0.0007, 
t(4) = 9.351. T4121: 2 d, P < 0.0001, t(4) = 19.147; 4 d, P < 0.0001, t(4) = 21.366; 6 d, P < 
0.0001, t(4) = 27.708. (d) Two independent shRNAs targeting ADSL decreased the growth 
of T387 (top) and T4121 (bottom) BTICs in comparison to a non-targeting control shRNA 
(shCont), as measured by direct cell number count. Two-tailed unpaired Student’s t-test; **P 
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< 0.01; n = 3 independent experiments per group. Data are presented as median ± s.e.m. 
(T387: 3 d, shRNA-1, P = 0.0004, t(4) = 11.280; shRNA-2, P = 0.0001, t(4) = 14.945; 5 d, 
shRNA-1, P < 0.0001, t(4) = 42.426; shRNA-2, P < 0.0001, t(4) = 25.324. T4121: 3 d, 
shRNA-1, P = 0.0018, t(4) = 7.379; shRNA-2, P = 0.0018, t(4) = 7.391; 5 d, shRNA-1, P = 
0.0001, t(4) = 14.215; shRNA-2, P = 0.0009, t(4) = 8.960.) (e) Two independent shRNAs 
targeting ADSL decreased the growth of T387 (top) and T4121 (bottom) BTICs in 
comparison to shCont, as measured by cell-titer assay. Two-tailed unpaired Student’s t-test; 
**P < 0.01; n = 6 independent experiments per group. (T387: 3 d, shRNA-1, P < 0.0001, 
t(10) = 9.842; shRNA-2, P < 0.0001, t(10) = 10.423; 5 d, shRNA-1, P < 0.0001, t(10) = 
45.883; shRNA-2, P < 0.0001, t(10) = 35.452. T4121: 3 d, shRNA-1, P < 0.0001, t(10) = 
7.161; shRNA-2, P < 0.0001, t(10) = 9.656; 5 d, shRNA-1, P < 0.0001, t(10) = 13.049; 
shRNA-2, P < 0.0001, t(10) = 13.473.) (f) In vitro extreme limiting dilution assays (ELDAs) 
demonstrate that knockdown of ADSL in T387 (top) and T4121 (bottom) BTICs decreases 
the frequency of neurosphere formation (T387, P < 0.0001; T4121, P < 0.0001 by ELDA 
analysis). (g) Knockdown of ADSL in T387 (top) and T4121 (bottom) BTICs decreases the 
number of spheres formed in ELDA per 1,000 cells seeded. Two-tailed unpaired Student’s t-
test; **P < 0.0001; n = 6 independent experiments per group. (T387: shRNA-1, t(10) = 
23.115; shRNA-2, t(10) = 21.493. T4121: shRNA-1, t(10) = 27.062; shRNA-2, t(10) = 
23.890.) (h) Representative images of neurospheres derived from T387 (left) and T4121 
(right) BTICs expressing shCont, shADSL-1 or shADSL-2. Scale bar, 100 μm. Each image 
is representative of at least 5 similar experiments. (i) Kaplan-Meier survival curves of 
immunocompromised mice bearing intracranial T387 (top) or T4121 (bottom) BTICs 
expressing shCont, shADSL-1 or shADSL-2. (T387, P < 0.0001; T4121, P = 0.0002 by log-
rank test; n = 5 animals per group). (j) Representative images of hematoxylin and eosin 
stained sections of mouse brains collected on day 18 after transplantation of T387 (top) or 
T4121 (bottom) BTICs expressing shCont, shADSL-1 or shADSL-2. Scale bar, 2 mm. Each 
image is representative of at least 3 similar experiments. In a,e,g, center line represents the 
median, lower and upper limits of the box represent the 25th and 75th percentiles, and 
whiskers show maximum and minimum.
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Figure 6. 
GMPS regulates BTIC growth and self-renewal. (a) Microarray-based gene expression level 
of GMPS from 542 glioblastoma (GBM) specimens and 10 different specimens of normal 
brain tissues. Expression data were derived from the TCGA glioblastoma data set (P < 
0.0001, t(550) = 10.818, two-tailed unpaired Student’s t-test). (b) H3K27ac ChIP-seq 
enrichment plot centered at the gene locus for GMPS. Enrichment is shown for three 
matched pairs of DGCs and BTICs from patient-derived glioblastoma specimens. H3K27ac 
ChIP-seq data were downloaded from NCBI Gene Expression Omnibus GSE54047. (c) qRT-
PCR quantification of GMPS mRNA levels in BTICs and DGCs. BTICs derived from three 
primary human glioblastoma specimens (T3691, T387, T4121) were treated with serum to 
induce differentiation over a course of 2, 4 or 6 d. Two-tailed unpaired Student’s t-test; **P 
< 0.01; n = 3 independent experiments per group. Data are presented as median ± s.e.m. 
(T3691: 2 d, P = 0.0003, t(4) = 11.523; 4 d, P < 0.0001, t(4) = 35.939; 6 d, P < 0.0001, t(4) = 
26.326. T387: 2 d, P = 0.0008, t(4) = 9.076; 4 d, P = 0.0006, t(4) = 9.748; 6 d, P = 0.0010, 
t(4) = 8.561. T4121: 2 d, P = 0.951, t(4) = 0.066; 4 d, P = 0.0018, t(4) = 10.669; 6 d, P = 
0.0001, t(4) = 15.436.) (d) Two independent shRNAs targeting GMPS decreased the growth 
of T387 (top) and T4121 (bottom) BTICs in comparison to a non-targeting control shRNA, 
as measured by direct cell number count. Two-tailed unpaired Student’s t-test; **P < 0.01; n 
= 3 independent experiments per group. Data are presented as median ± s.e.m. T387: 3 d, 
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shRNA-1, P = 0.0051, t(4) = 13.914; shRNA-2, P = 0.0048, t(4) = 14.422; 5 d, shRNA-1, P 
= 0.0016, t(4) = 24.686; shRNA-2, P = 0.0012, t(4) = 27.858. T4121: 3 d, shRNA-1, P = 
0.0003, t(4) = 56.569; shRNA-2, P = 0.0012, t(4) = 24.033; 5 d, shRNA-1, P = 0.0013, t(4) = 
26.916; shRNA-2, P = 0.0014, t(4) = 26.845. (e) Two independent shRNAs targeting GMPS 
decreased the growth of T387 (top) and T4121 (bottom) BTICs in comparison to a non-
targeting control shRNA, as measured by cell-titer assay. Two-tailed unpaired Student’s t-
test; **P < 0.01; n = 6 independent experiments per group. (T387: 3 d, shRNA-1, P < 
0.0001, t(10) = 13.910; shRNA-2, P < 0.0001, t(10) = 14.932; 5 d, shRNA-1, P < 0.0001, 
t(10) = 13.856; shRNA-2, P < 0.0001, t(10) = 13.841. T4121: 3 d, shRNA-1, P < 0.0001, 
t(10) = 20.981; shRNA-2, P < 0.0001, t(10) = 20.981; 5 d, shRNA-1, P < 0.0001, t(10) = 
21.738; shRNA-2, P < 0.0001, t(10) = 21.924.) (f) In vitro extreme limiting dilution assays 
(ELDA) demonstrate that knockdown of GMPS in T387 (top) and T4121 (bottom) BTICs 
decreases the frequency of neurosphere formation (T387, P < 0.0001; T4121, P < 0.0001, by 
ELDA analysis). (g) Knockdown of GMPS in T387 (top) and T4121 (bottom) BTICs 
decreases the number of spheres formed in ELDA per 1,000 cells seeded. Two-tailed 
unpaired Student’s t-test; **P < 0.0001; n = 6 independent experiments per group. (T387: 
shRNA-1, t(10) = 32.575; shRNA-2, t(10) = 32.367. T4121: shRNA-1, t(10) = 26.678; 
shRNA-2, t(10) = 26.638.) (h) Representative images of neurospheres derived from T387 
(left) and T4121 (right) BTICs expressing shCont, shGMPS-1 or shGMPS-2. Scale bar, 100 
μm. Each image is representative of at least 5 similar experiments. (i) Kaplan-Meier survival 
curves of immunocompromised mice bearing intracranial T387 (top) or T4121 (bottom) 
BTICs expressing shCont, shGMPS-1 or shGMPS-2. (T387, P = 0.0001; T4121, P = 0.0003 
by log-rank test; n = 5 animals per group). (j) Representative images of hematoxylin and 
eosin stained sections of mouse brains collected on day 18 after transplantation of T387 
(top) or T4121 BTICs expressing shCont, shGMPS-1 or shGMPS-2. Scale bar, 2 mm. Each 
image is representative of at least 3 similar experiments. In a,e,g, center line represents the 
median, lower and upper limits of the box represent the 25th and 75th percentiles, and 
whiskers show maximum and minimum.
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Figure 7. 
PRPS1 regulates BTIC growth and self-renewal. (a) Microarray-based gene expression level 
of PRPS1 from 542 glioblastoma (GBM) specimens and 10 different specimens of normal 
brain tissues. Expression data were derived from the TCGA glioblastoma data set (P = 
0.0003, t(550) = 4.719, two-tailed unpaired Student’s t-test). (b) H3K27ac ChIP-seq 
enrichment plot centered at the gene locus for PRPS1. Enrichment is shown for three 
matched pairs of DGCs and BTICs from patient-derived glioblastoma specimens. H3K27ac 
ChIP-seq data were downloaded from NCBI Gene Expression Omnibus GSE54047. (c) qRT-
PCR quantification of PRPS1 mRNA levels in BTICs and DGCs. BTICs derived from three 
primary human glioblastoma specimens (T3691, T387, T4121) were treated with serum to 
induce differentiation into DGCs, with time points taken at 2, 4 and 6 d. Two-tailed unpaired 
Student’s t-test; *P < 0.05; **P < 0.01; n = 3 independent experiments per group. Data are 
presented as median ± s.e.m. (T3691: 2 d, P = 0.3309, t(4) = 1.106; 4 d, P = 0.0109, t(4) = 
4.487; 6 d, P = 0.0028, t(4) = 6.576. T387: 2 d, P = 0.0005, t(4) = 16.496; 4 d, P < 0.0001, 
t(4) = 22.363; 6 d, P < 0.0001, t(4) = 20.931. T4121: 2 d, P = 0.0022, t(4) = 6.946; 4 d, P = 
0.0018, t(4) = 7.388; 6 d, P = 0.0092, t(4) = 4.671.) (d) Two independent shRNAs targeting 
PRPS1 decreased the growth of T387 (top) and T4121 (bottom) BTICs in comparison to a 
non-targeting control shRNA, as measured by direct cell number count. Two-tailed unpaired 
Student’s t-test; **P < 0.01; n = 3 independent experiments per group. Data are presented as 
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median ± s.e.m. T387: 3 d, shRNA-1, P = 0.0029, t(4) = 18.336; shRNA-2, P = 0.0030, t(4) 
= 17.441; 5 d, shRNA-1, P = 0.0002, t(4) = 63.302; shRNA-2, P = 0.0004, t(4) = 53.000. 
T4121: 3 d, shRNA-1, P = 0.0136, t(4) = 8.485; shRNA-2, P = 0.0062, t(4) = 12.611; 5 d, 
shRNA-1, P = 0.0088, t(4) = 10.590; shRNA-2, P = 0.0079, t(4) = 11.207. (e) Two 
independent shRNAs targeting PRPS1 decreased the growth of T387 (top) and T4121 
(bottom) BTICs in comparison to a non-targeting control shRNA, as measured by cell-titer 
assay. Two-tailed unpaired Student’s t-test; **P < 0.0001; n = 6 independent experiments 
per group. (T387: 3 d, shRNA-1, t(10) = 40.496; shRNA-2, t(10) = 38.005; 5 d, shRNA-1, 
t(10) = 47.379; shRNA-2, t(10) = 42.150. T4121: 3 d, shRNA-1, t(10) = 7.316; shRNA-2, 
t(10) = 23.789; 5 d, shRNA-1, t(10) = 15.959; shRNA-2, t(10) = 39.988.) (f) In vitro extreme 
limiting dilution assays (ELDA) demonstrate that knockdown of PRPS1 in T387 (top) and 
T4121 (bottom) BTICs decreases the frequency of neurosphere formation. (T387, P < 
0.0001; T4121, P < 0.0001 by ELDA analysis). (g) Knockdown of PRPS1 in T387 (top) and 
T4121 (bottom) BTICs decreases the number of neurospheres formed in ELDA per 1,000 
cells seeded. Two-tailed unpaired Student’s t-test; **P < 0.0001; n = 6 independent 
experiments per group. (T387: shRNA-1, t(10) = 14.805; shRNA-2, t(10) = 13.952. T4121: 
shRNA-1, t(10) = 20.889; shRNA-2, t(10) = 20.584.) (h) Representative images of 
neurospheres derived from T387 (left) and T4121 (right) BTICs expressing shCont, 
shPRPS1-1 or shPRPS1-2. Scale bar, 100 μm. Each image is representative of at least 5 
similar experiments. (i) Kaplan-Meier survival curves of immunocompromised mice bearing 
intracranial T387 (top) or T4121 (bottom) BTICs expressing shCont, shPRPS1-1 or 
shPRPS1-2. (T387, P = 0.0011; T4121, P = 0.0002 by log-rank test; n = 5 animals per 
group). (j) Representative images of hematoxylin and eosin stained sections of mouse brains 
collected on day 18 after transplantation of T387 (top) or T4121 BTICs expressing shCont, 
shPRPS1-1 or shPRPS1-2. Scale bar, 2 mm. Each image is representative of at least 3 
similar experiments. In a,e,g, center line represents the median, lower and upper limits of the 
box represent the 25th and 75th percentiles, and whiskers show maximum and minimum.
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Figure 8. 
Overexpression of purine synthesis genes is associated with poor brain tumor patient 
survival. (a) Analysis of the TCGA glioblastoma data set indicates a significant correlation 
between reduced expressions of purine synthesis genes (PPAT, ADSL, ADSS and IMPDH1) 
and overall survival in all patients. Log-rank test. (ADSLlow, n = 256; ADSLhigh, n = 261; P 
= 0.0056. ADSSlow, n = 338; ADSShigh, n = 179; P = 0.0376. IMPDH1low, n = 279; 
IMPDH1high, n = 238; P = 0.0325. PPATlow, n = 382; PPAThigh, n = 135; P = 0.0111.) (b) 
Analysis of the Freije high-grade glioma data set indicates a significant inverse correlation 
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between expression of purine synthesis genes (PPAT and IMPDH1) and overall survival in 
all patients. Log-rank test. (PPATlow, n = 49; PPAThigh, n = 37; P = 0.0068. IMPDH1low, n = 
50; IMPDH1high, n = 36; P = 0.0025.) (c) Analysis of the Phillips high-grade glioma data set 
indicates a significant correlation between reduced expressions of purine synthesis enzymes 
(PPAT and ADSS) and overall survival in all patients. Log-rank test. (PPATlow, n = 53; 
PPAThigh, n = 24; P = 0.0069. ADSSlow, n = 57; ADSShigh, n = 20; P = 0.0004.)
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